Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)

NCT06419179 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Carcinoma

Interventions

DRUG: Durvalumab
DRUG: Olaparib

Sponsor

University of Cologne

Collaborators

[object Object]